



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
Silver Spring MD 20993

NDA 21571/S-006

**SUPPLEMENT APPROVAL**

Santen Incorporated  
Attention: Crystal Browning, MS  
Director, Head of Regulatory Affairs  
2100 Powell Street, 16<sup>th</sup> Floor  
Emeryville, CA 94608

Dear Ms. Browning:

Please refer to your Supplemental New Drug Application (sNDA) dated and received on October 31, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for IQUIX (levofloxacin ophthalmic solution) 1.5%.

We acknowledge receipt of your amendments dated June 6 and November 21, 2014. The June 6, 2014, submission constituted a complete response to our Complete Response letter dated June 18, 2013.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text and with the minor editorial revision correcting the approval date for the molecular entity to read, "1996." This change can be implemented at the next printing.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert, except with the revisions listed above, and with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes with the revisions listed above approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Ms. Lois Almoza, Regulatory Health Project Manager, at (301) 796-1600.

Sincerely,

*{See appended electronic signature page}*

Wiley A. Chambers, MD  
Deputy Director  
Division of Transplant and Ophthalmology  
Products  
Office of Antimicrobial Products  
Center for Drug Evaluation and Research

ENCLOSURE:  
Package Insert

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

WILEY A CHAMBERS  
12/03/2014